Introduction
============

Recent years have witnessed unprecedented growth of research and applications in the area of nanoscience and nanotechnology. There is increasing optimism that nanotechnology, as applied to medicine, will bring significant advances in the diagnosis and treatment of disease. Anticipated applications in medicine include drug delivery, both in vitro and in vivo diagnostics, nutraceuticals and production of improved biocompatible materials ([@b39]; [@b28]; [@b45]; [@b44]; [@b50]). Engineered nanoparticles are an important tool to realize a number of these applications. It has to be recognized that not all particles used for medical purposes comply to the recently proposed and now generally accepted definition of a size ≤100 nm ([@b145]). However, this does not necessarily has an impact on their functionality in medical applications. The reason why these nanoparticles (NPs) are attractive for medical purposes is based on their important and unique features, such as their surface to mass ratio that is much larger than that of other particles, their quantum properties and their ability to adsorb and carry other compounds. NPs have a relatively large (functional) surface which is able to bind, adsorb and carry other compounds such as drugs, probes and proteins. However, many challenges must be overcome if the application of nanotechnology is to realize the anticipated improved understanding of the patho-physiological basis of disease, bring more sophisticated diagnostic opportunities, and yield improved therapies. Although the definition identifies nanoparticles as having dimensions below 0.1 μm or 100 nm, especially in the area of drug delivery relatively large (size \>100 nm) nanoparticles may be needed for loading a sufficient amount of drug onto the particles. In addition, for drug delivery not only engineered particles may be used as carrier, but also the drug itself may be formulated at a nanoscale, and then function as its own "carrier" ([@b19]; [@b5]; [@b39]; [@b73]). The composition of the engineered nanoparticles may vary. Source materials may be of biological origin like phospholipids, lipids, lactic acid, dextran, chitosan, or have more "chemical" characteristics like various polymers, carbon, silica, and metals. The interaction with cells for some of the biological components like phospholipids will be quite different compared to the non biological components such as metals like iron or cadmium. Especially in the area of engineered nanoparticles of polymer origin there is a vast area of possibilities for the chemical composition.

Although solid NPs may be used for drug targeting, when reaching the intended diseased site in the body the drug carried needs to be released. So, for drug delivery biodegradable nanoparticle formulations are needed as it is the intention to transport and release the drug in order to be effective. However, model studies to the behavior of nanoparticles have largely been conducted with non-degradable particles. Most data concerning the biological behavior and toxicity of particles comes from studies on inhaled nanoparticles as part of the unintended release of ultrafine or nanoparticles by combustion derived processes such as diesel exhaust particles (reviewed by [@b110]; [@b35], [@b36]; [@b8]; [@b34]; [@b38]; [@b9]; [@b112]). Research has demonstrated that exposure to these combustion derived ultrafine particles/nanoparticles is associated with a wide variety of effects ([@b37]) including pulmonary inflammation, immune adjuvant effects ([@b56]) and systemic effects including blood coagulation and cardiovascular effects ([@b9]; [@b112]). Since the cut-off size for both ultrafine and nanoparticles (100 nm) is the same, now both terms are used as equivalent. Based on the adverse effects of ultrafine particles as part of environmental pollution, engineered nanoparticles may be suspected of having similar adverse effects. It is the purpose of this review to use this database on combustion derived nanpoarticles (CDNP) obtained by inhalation toxicology and epidemiology and bridge the gap to engineered nanoparticles.

Nanoparticles and drug delivery
===============================

Drug delivery and related pharmaceutical development in the context of nanomedicine should be viewed as science and technology of nanometer scale complex systems (10--1000 nm), consisting of at least two components, one of which is a pharmaceutically active ingredient ([@b39]; [@b50]), although nanoparticle formulations of the drug itself are also possible ([@b5]; [@b19]; [@b39]; [@b73]). The whole system leads to a special function related to treating, preventing or diagnosing diseases sometimes called smart-drugs or theragnostics ([@b85]). The primary goals for research of nano-bio-technologies in drug delivery include:

-   More specific drug targeting and delivery,

-   Reduction in toxicity while maintaining therapeutic effects,

-   Greater safety and biocompatibility, and

-   Faster development of new safe medicines.

The main issues in the search for appropriate carriers as drug delivery systems pertain to the following topics that are basic prerequisites for design of new materials. They comprise knowledge on (i) drug incorporation and release, (ii) formulation stability and shelf life (iii) biocompatibility, (iv) biodistribution and targeting and (v) functionality. In addition, when used solely as carrier the possible adverse effects of residual material after the drug delivery should be considered as well. In this respect biodegradable nanoparticles with a limited life span as long as therapeutically needed would be optimal.

[Table 1](#tbl1){ref-type="table"} presents some of the types of chemical structures and possibilities for the preparation of nanoscale materials used as pharmaceutical carrier system (reviewed in [@b10]). Certainly none of the so far developed carriers fulfill all the parameters mentioned above to the full extent; the progress made in nanotechnology inter alia emerging from the progress in the polymer-chemistry, however, can provide an intriguing basis to tackle this issue in a promising way.

###### 

Overview of nanoparticles and their applications in Life Sciences

  ---------------------------------------------------------------------------------
  Particle class                     Materials               Application
  ---------------------------------- ----------------------- ----------------------
  Natural materials or derivatives   Chitosan\               Drug/Gene delivery
                                     Dextrane\               
                                     Gelatine\               
                                     Alginates\              
                                     Liposomes\              
                                     Starch                  

  Dendrimers                         Branched polymers       Drug delivery

  Fullerenes                         Carbon based carriers   Photodynamics\
                                                             Drug delivery

  Polymer carriers                   Polylactic acid\        Drug/gene delivery
                                     Poly(cyano)acrylates\   
                                     Polyethyleinemine\      
                                     Block copolymers\       
                                     Polycaprolactone        

  Ferrofluids                        SPIONS\                 Imaging (MRI)
                                     USPIONS                 

  Quantum dots                       Cd/Zn-selenides         Imaging\
                                                             In vitro diagnostics

  Various                            Silica-nanoparticles\   Gene delivery
                                     Mixtures of above       
  ---------------------------------------------------------------------------------

The aims for nanoparticle entrapment of drugs are either enhanced delivery to, or uptake by, target cells and/or a reduction in the toxicity of the free drug to non-target organs. Both situations will result in an increase of therapeutic index, the margin between the doses resulting in a therapeutic efficacy (eg, tumor cell death) and toxicity to other organ systems. For these aims, creation of long-lived and target-specific nanoparticles is needed. Chemical formulations under investigation are shown in [Table 2](#tbl2){ref-type="table"}. Most of the compounds are biodegradable polymers resulting in drug release after degradation. One of the problems in the use of particulate drug carriers including nanomaterials is the entrapment in the mononuclear phagocytic system as present in the liver and spleen ([@b86]; [@b53]; [@b29]; [@b99]). However, liver targeting of nanoparticles may be favorable when treating liver diseases like tumor metastasis or hepatitis. Surface modification with polyethylene glycol (PEG) resulted in prolonged presence in the circulation by inhibiting recognition and phagocytosis by the mononuclear phagocytic system ([@b6]; [@b119]; [@b107]). In addition to altering the distribution the PEG modification also reduced in vitro toxicity when gold nanorods were modified using PEG ([@b107]). Coating of NP may also be needed to prevent agglomeration. Several coatings can be used to prevent agglomeration and keeping the particles in colloidal suspension including various polymers like polyethylene glycol (PEG), poly(vinylpyrrolidone) (PVP) etc, natural polymers like dextran, chitosan, pullulan etc, and surfactants like sodium oleate, dodecylamine etc (reviewed by [@b59]).

###### 

Chemicals under investigation for drug delivery

  -------------------------------------------- -----------
  Albumin                                      [@b27]

  Cetyl alcohol/polysorbate                    [@b76]

  Chitosan                                     [@b41];\
                                               [@b67]

  Gelatin                                      [@b19]

  Gold                                         [@b60];\
                                               [@b116]

  Hydrogels                                    [@b58]

  Magnetic iron oxide                          [@b59]

  Methoxy                                      [@b72]

  poly(ethylene glycol)/poly(ε-caprolactone)   

  Polyalkylcyanoacrylate composites            [@b3];\
                                               [@b80]

  Poly(D,L-lactic-co-glycolic)acid (PLGA)      [@b117];\
                                               [@b149]

  Solid lipid formulations                     [@b102];\
                                               [@b151]
  -------------------------------------------- -----------

NP size can influence the NP distribution as was demonstrated for lipid vesicles for which a lower liver uptake was found for the smaller vesicles (200/300 nm versus 25/50 nm) ([@b133]). Even small size differences may be of influence for the actual distribution and thus bioavailability ([@b127]; [@b51]; [@b137]; [@b154]; [@b46]). For liposomes with sizes \>100 nm the clearance rate by the mononuclear phagocytic system increased with increasing size, while for sizes below 100 nm charge was more important ([@b135]; [@b134]). However, not all particles with sizes below 100 nm will behave similarly and composition will be important as well. Analogous to earlier findings on asbestiform and mineral fibers, the actual size and shape of nanomaterials will be of importance.

Besides degradation physical means such as heating and light may be used to provoke the therapeutic effect (cell death) or for local drug release, respectively. Thermosensitive nanoparticles may be used for selective release of the content after specific localization. An example of this principle is presented in [Figure 1](#fig1){ref-type="fig"}. For doxorubicin an enhanced cytotoxicity was observed in vitro at 42 °C compared to 37 °C using copolymers of polyethylene glycol (PEG) and poly-L-lactide (PLLA) ([@b103]). In addition, the release of photosensitizers from nanoformulations by light, so called photodynamic therapy, was able to induce cytotoxicity as demonstrated for PLGA nanoparticles containing zinc(II) phthalocyanine ([@b126]) and indocyanine green ([@b55]).

![Graph illustrating contactless controllable drug carrying system based on thermosensitive magnetic nano- and micro particles. The insert shows the application of the system with Rhodamine B encapsulated beads that is released after heating up to 45 °C.](ijn0302-133-01){#fig1}

Use of NP formulations in drug delivery
---------------------------------------

One of the major challenges in drug delivery is to get the drug at the place it is needed in the body thereby avoiding potential side effects to non diseased organs. This is especially challenging in cancer treatment where the tumor may be localized as distinct metastases in various organs. The non restricted (cyto)toxicity of chemotherapeutics thus limits the full use of their therapeutic potential. Local drug delivery or drug targeting results in increased local drug concentrations and provides strategies for more specific therapy. Nanoparticles have specific particles as tools to enable these strategies. These include benefits such as their small size which allows penetration of cell membranes, binding and stabilization of proteins, and lysosomal escape after endocytosis.

The entrapment of chemotherapeutics in nanosized formulations like liposomes has been already subject of study for considerable time (reviews: [@b26]; [@b95]; [@b97]). Liposomes as nanosized phospholipid "fatty" structures have the advantage of being small, flexible and biocompatible thus being able to pass along the smallest arterioles and endothelial fenestrations without causing clotting. Now also other materials, including various (co-)polymers and dendrimers at the nanosize range have become available to alter the distribution of encapsulated or attached drugs.

One of the therapeutics under intensive study is paclitaxel (taxol). For paclitaxel the nanoparticle formulation resulted in enhanced cytotoxicity for tumor cells in vitro, and at the same time an increased sustainable therapeutic efficacy in an in vivo animal model ([@b150]). The paclitaxel was encapsulated in vitamin E TPGS-emulsified poly (D,L-lactic-co-glycolic acid) (PLGA) nanoparticles, and this system resulted in a higher and prolonged level above the effective concentration in vivo, reflected in an increased area under the curve (AUC)

Apart from size the surface chemistry of particles is of crucial importance in particle uptake, distribution and effects. This was shown extensively with acute and chronic models of surface modified micro quartzes ([@b131]; [@b1]). Quartz which was coated with PVNO-polymer was taken op by macrophages without toxicity and showed no genotoxicity in epithelial cells or acute and chronic inflammation. On the other hand naïve quartz caused these effects to a large extent. An altered body distribution was demonstrated for two types of polymer particles ([@b147]). Only PMMA (about 1.4 μm and about 6.4 μm) particles but not PS (about 1.2 μm, 5.2 μm and 12.5 μm) particles could be recovered form the spleen after intraperitoneal administration ([@b147]). Whether a similar situation exists for nanoparticles is unknown, but studies with surface modified polystyrene particles do suggest different effects on blood coagulation ([@b106]), mitochondrial ROS formation and cellular oxidative burst ([@b152]). In addition, as mentioned above the coating of nanoparticles with polyethylene glycol (PEG) increases the time in circulation for the nanoparticles ([@b6]; [@b119]; [@b107]).

The aims for nanoparticle entrapment of drugs are either enhanced delivery to, or uptake by, target cells and/or a reduction in the toxicity of the free drug to non-target organs. For these aims, creation of long-lived and target-specific nanoparticles is needed. One of the problems is the entrapment of nanoparticles in the mononuclear phagocytic system as present in the liver and spleen ([@b86]; [@b53]; [@b29]; [@b99]). However, liver targeting of nanoparticles may be favorable when treating liver diseases like tumor metastasis or hepatitis. Also oligonucleotides for modification of gene expression were demonstrated to migrate into the liver when bound to biodegradable polyalkylcyanoacrylate nanoparticles ([@b47]). Surface modification with PEG resulted in prolonged presence in the circulation by inhibiting recognition and phagocytosis by the mononuclear phagocytic system ([@b6]; [@b119]; [@b107]). Besides reduction of therapeutic efficacy, liver entrapment may also have an adverse effect on liver function. For cyanoacrylate and polystyrene nanoparticles (about 214 nm and about 128 nm, respectively) transient liver alterations were observed after acute and chronic intravenous administration ([@b48], [@b49]). Inflammatory responses were characterized by secretion of acute phase protein α1-acid glycoprotein by hepatocytes ([@b48]). In addition, antioxidant defenses of hepatocytes were depleted probably as a result of local release of oxidative species ([@b37]).

Although nanoformulation is aimed at enhancing drug delivery without loss of drug activity, in a study comparing insulin-chitosan nanoparticles to chitosan solution and chitosan powder formulations the insulin-chitosan nanoparticles were less effective in terms of bioavailability and lowering blood glucose level in both a rat and sheep model ([@b41]).

Cellular and intracellular targets
----------------------------------

For drug delivery not only organ or cellular targeting is of importance but also the fate of the nanoparticles within the cells. Particles generally end intracellularly in endosomes or lysosomes followed by degradation. For activity of the encapsulated drugs release into the cytosol is needed. However, for nanoparticles of about 20 nm also cellular uptake without contribution by endocytic mechanisms was demonstrated ([@b42]). Chemical characteristics such as surface charge may also determine the fate of nanoparticles in cells. Surface functionalization of gold nanoparticles with PEG resulted in efficient internalization in endosomes and cytosol, and localized in the nuclear region ([@b136]). Poly(DL-lactide-co-glycolide) nanoparticles were found to be ingested by cells by endocytosis ([@b117]; [@b75]). The escape from these endosomes into the cellular cytoplasm was suggested to be caused by a change in surface charge form negative to positive of the PLGA nanoparticles resulting in cytoplasmic delivery of the incorporated drugs. The hypothesis that the positive surface charge influenced the escape of the endosomes was supported by data obtained with negatively charged polystyrene nanoparticles which did not reach the cytosol but remained in the endosomal compartment of the smooth muscle cells used in this study ([@b117]).

Specific targeting to retinal pigment epithelium cells in the eye is possible ([@b12]). Very small quantum dots (\<10 nm) have been used for specific targeting of peptide coated dots to the vasculature of lungs and tumors ([@b2]). In addition, polymer shells on the quantum dots might be linked to targeting molecules. For example quantum dots cores can be coated with hydrophilic polyethylene glycol (PEG) to increase the half life time ([@b4]). However, also uptake by lymph nodes was demonstrated in which the quantum dots could be observed up until 4 months after administration, so accumulation seems likely ([@b4]). PEG coating abrogated uptake by the reticuloendothelial system of liver and spleen. In contrast about 40--50 nm magnetic nanoparticles coated with PEG were quite well taken up by endocytosis ([@b58]).

Surface modifications of nanoparticles offer possibilities for medical applications like drug targeting in terms of cellular binding, uptake and intracellular transport. Carbohydrate binding ligands on the surface of biodegradable and biocompatible poly(D,L-lactic-co-glycolide)acid (PLGA) nanospheres were found to increase cellular binding ([@b149]). Such increased adherence may lead to an enhanced activity of the drug presented as or incorporated in nanoparticles. Coupling specific proteins such as antibodies to the nanoparticle surface may enable a more specific immunologically directed targeting of the particles ([@b108]; [@b121]).

The Brain -- the ultimate target for drug delivery
--------------------------------------------------

From several perspectives the brain is a challenging organ for drug delivery. First, the incidence of degenerative diseases in the brain will increase with the aging population. Secondly, the blood brain barrier (BBB) is well-known as the best gatekeeper in the body toward exogenous substances (review [@b118]). Generally pharmaceuticals including most small molecules do not cross the BBB. The endothelial barrier is specifically tight at the interface with the brain astrocytes and can in normal conditions only be passed using endogeneous BBB transporters resulting in carrier mediated transport, active efflux transport and/or receptor mediated transport. However the barrier properties may be compromised intentionally or unintentionally by drug treatment allowing passage of nanoparticles ([@b114]; [@b80]; [@b89]; [@b77]). The delivery of drugs by nanocarrier was recently reviewed ([@b77]; [@b146]).

Passage of the BBB was suggested to be possible by the toxic effect of nanoparticles (about 200 nm) on cerebral endothelial cells ([@b114]), although for similar nanoparticles (about 300 nm) this was contradicted in another study ([@b80]). In addition this effect was not found for a different type of nanoparticles ([@b89]). Physical association of the drug to the nanoparticles was necessary for drug delivery to occur into the brain ([@b80]). When nanoparticles with different surface characteristics were evaluated, neutral nanoparticles and low concentrations of anionic nanoparticles were found to have no effect on BBB integrity, whereas high concentrations of anionic nanoparticles and cationic nanoparticles were toxic for the BBB. The extent of brain uptake of anionic nanoparticles at lower concentrations was superior to neutral or cationic formulations at the same concentrations. So, nanoparticle surface charges must be considered for toxicity and brain distribution profiles ([@b88]). Especially coating of the nanoparticles with the polysorbate (Tween) surfactants resulted in transport of drugs across the blood brain barrier ([@b79]). The mechanism for transport was suggested to be endocytosis via the Low Density Lipoprotein (LDL) receptor of the endothelial cells after adsorption of lipoproteins form blood plasma to the nanoparticles ([@b78], [@b79]). Additional investigations revealed the role of apolipoprotein-E for transport of drugs across the BBB while apolipoprotein-E variants that did not recognized lipoprotein receptors failed in transporting the drug across the BBB ([@b96]). It was suggested that the recognition and interaction with lipoprotein receptors on brain capillary endothelial cells was responsible for the brain uptake of the drug.

Passage of the BBB may also be achieved by masking certain drug characteristics preventing or limiting binding to cellular efflux systems like p-glycoprotein, a cellular transporter associated with drug removal from cells. P-glycoprotein is one of the ATP dependent efflux transporters that has an important physiological role in limiting drug entry into the brain ([@b54]; Sharom 2006). In addition, p-glycoprotein also designated the multidrug resistance protein may be highly expressed in drug resistant tumor cells. Surfactant coated poly(butyl) cyanoacrylate nanoparticles have been used to deliver drugs to the CNS ([@b3]) The effect of entrapment of a cytotoxic drug paclitaxel (PX) in cetyl alcohol/polysorbate nanoparticles (PX NP) was evaluated in an in situ rat brain perfusion model ([@b76]). The results suggest that entrapment of paclitaxel in nanoparticles significantly increases the brain drug uptake and its toxicity towards p-glycoprotein expressing tumor cells (p-glycoprotein is an efflux transporter associated with drug removal from the cells). It was hypothesized that PX nanoparticles limit paclitaxel binding to p-glycoprotein and subsequent efflux from the cells, which consequently would lead to higher brain and tumor cell levels.

Other routes for reaching the brain, circumventing the BBB, may be via migration along the olfactory or trigeminal nerve endings after deposition on the olfactory mucosa in the nasal region ([@b109]). Translocation of ultrafine ^13^C particles (35 nm) was detected by using this isotope measurement in the brain olfactory bulb after inhalation exposure. Also other solid NP like manganese oxide was shown to translocate to the brain by the olfactory route ([@b43]), based on measurements of manganese in different parts of the brain. In order to increase the specific uptake via the inhalation route nanoparticles have been functionalized by conjugation with bioactive ligands-lectins to the surface of poly (ethylene glycol)- poly (lactid acid) (PEG-PLA) nanoparticles. Wheat germ agglutinin (WGA) was used which binds to N-acetyl-D-glucosamine and sialic acid both of which are abundantly present in the nasal cavity. There was a twofold increase in the brain uptake of such functionalized NP ([@b52]). However, it needs to be stated that both passage of the BBB and the olfactory route only account for up to 2% nanoparticles uptake, and its efficacy with regard to drug delivery needs to make considerable increments before use.

Toxicological hazards of nanoparticles
======================================

General concepts
----------------

To use the potential of Nanotechnology in Nanomedicine, full attention is needed to safety and toxicological issues. For pharmaceuticals specific drug delivery formulations may be used to increase the so called therapeutic ratio or index being the margin between the dose needed for clinical efficacy and the dose inducing adverse side effects (toxicity). However, also for these specific formulations a toxicological evaluation is needed. This is particularly true for the applications of nanoparticles for drug delivery. In these applications particles are brought intentionally into the human body and environment, and some of these new applications are envisaged an important improvement of health care ([@b14]; [@b44]; [@b50]). Opinions started to divert when toxicologists claimed that new science, methods and protocols are needed ([@b8]; [@b104]). However, the need for this is now underlined by several expert reports ([@b111]; [@b130]) and more importantly by the following concepts:

1.  Nanomaterials are developed for their unique (surface) properties in comparison to bulk materials. Since surface is the contact layer with the body tissue, and a crucial determinant of particle response, these unique properties need to be investigated from a toxicological standpoint. When nanoparticles are used for their unique reactive characteristics it may be expected that these same characteristics also have an impact on the toxicity of such particles. Although current tests and procedures in drug and device evaluation may be appropriate to detect many risks associated with the use of these nanoparticles, it cannot be assumed that these assays will detect all potential risks. So, additional assays may be needed. ([@b130]) This may differ depending on the type of particles used, ie, biological versus non-biological origin.

2.  Nanoparticles are attributed qualitatively different physico-chemical characteristics from micron-sized particles, which may result in changed body distribution, passage of the blood brain barrier, and triggering of blood coagulation pathways. In view of these characteristics specific emphasis should be on investigations in (pharmaco)kinetics and distribution studies of nanoparticles. What is currently lacking is a basic understanding of the biological behavior of nanoparticles in terms of distribution in vivo both at the organ and cellular level.

3.  Effects of combustion derived nanoparticles in environmentally exposed populations mainly occur in diseased individuals. Typical pre-clinical screening is almost always done in healthy animals and volunteers and risks of particles may therefore be detected at a very late stage.

It may be argued that some if not all of these specific effects will be detected during routine testing and post marketing evaluation after clinical use. All would depend on the types of assays used in the preclinical evaluation, which should be considered in the light of the use of the final products. In addition, one cannot rely on the toxicological profile of the bulk material when that material is used in a nanoformulation. What is clear is that the safety evaluation and the risk benefit analysis need to be performed on a case by case basis.

The use of nanoparticles as drug carrier may reduce the toxicity of the incorporated drug. In general the toxicity of the whole formulation is investigated while results of the nanoparticles itself are not described. So, discrimination between drug and nanoparticle toxicity cannot be made. So, there should be a specific emphasis on the toxicity of the "empty" non-drug loaded particles. This is especially important when slowly or non degradable particles are used for drug delivery which may show persistence and accumulation on the site of the drug delivery, eventually resulting in chronic inflammatory reactions.

Evidence for nanoparticle toxicity
----------------------------------

The largest database on the toxicity of nanoparticles has originated from inhalation toxicology including the PM~10~ literature (particulate matter with a size below 10 mm), where the 'NP hypothesis' has proved to be a powerful drive for research ([@b33], [@b36]; [@b112]; [@b11]). An overview of particle terminology in relation to ambient effects is given in [Table 3](#tbl3){ref-type="table"}. Therefore it relevant to discuss this evidence in the expectation that it will shed light on the toxicity of engineered NPs. The idea that combustion-derived NPs are an important component that drives the adverse effects of environmental particulate air pollution or PM~10~ comes from several sources:

###### 

Various denominations of particles in inhalation toxicology and drug delivery in relation to their source (ambient, bulk, engineered)

  Particle type                   Description
  ------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PM~10~, PM~2.5~                 Particle mass fraction in ambient air with a mean diameter of 10 or 2.5 μm respectively. Basis of current standards for ambient particles in Europe and USA
  Coarse particles                The mass fraction of PM~10~, which is bigger than 2.5 μm
  Ultrafine particles (PM~0.1~)   The fraction of PM~10~ with a size cut-off at 0.1 μm. Contains primary particles and agglomerates smaller than 100 nm
  PSP                             Poorly soluble particles with low specific toxicity. Maybe be fine or ultrafine. Terminology used in relation to bulk synthetic particles. Examples TiO~2~, carbon blacks, Amorphous silica, Iron oxides (Fe~2~O~3~), Zinc oxides (ZnO)
  CDNP                            Combustion derived nanoparticles, such as diesel exhaust particles (DEP)
  DEP                             Diesel exhaust particles

1.  Much of the mass of PM~10~ is considered to be non-toxic and so there has arisen the idea that there is a component(s) of PM~10~ that actually drives the pro-inflammatory effects and combustion-derived NP seems a likely candidate.

2.  Nanoparticles are the dominant particle type by number suggesting that they may be important and their small size means that they have a large surface area per unit mass. Particle toxicology suggests that, for toxic particles generally, more particle surface equals to more toxicity.

3.  Substantial toxicological data and limited data from epidemiological sources support the contention that NPs in PM~10~ are important drivers of adverse effects.

The adverse health effects of particulate matter (PM) are measurable as exacerbations of respiratory disease and deaths as well as hospitalizations and deaths from respiratory and cardiovascular disease ([@b31]; [@b13]; [@b120]). Inflammation is the common factor that binds together these adverse effects and the ability of NPs to cause inflammation can be seen as an important property. It is not clear what effects of NPs have pulmonary inflammation as a prerequisite and what effects could potentially be driven by exposures below those causing inflammation. There is also the potential for pulmonary inflammation to result in changes in membrane permeability that in turn may impact the potential for particles to distribute beyond the lung. Some NPs may have the extra potential of affecting cardiovascular disease directly. Vascular function was impaired after inhalation of diesel exhaust particles ([@b98]). However, data to date are limited and not all studies of nanoparticles have shown significant translocation from lung to the blood. In some studies translocation has been rather minimal ([@b82]; [@b144]). Understanding clearance kinetics of inhaled ambient air nanoparticles will also be important in understanding their potential for adverse effects.

The current paradigm in particle toxicology is that ultrafine ambient air particles have the potential of affecting cardiovascular disease both indirectly via pulmonary inflammation and directly through particle distribution. Although important, this property of redistribution has yet to be demonstrated for NPs present in real PM10. It should be noted that there are several mechanisms whereby NPs could lead to inflammatory effects, as is the case for larger particles. These mechanisms are either based on the large surface area of particle core or on soluble components released by the NPs. In addition various chemicals including those of biological origin like endotoxin may be adsorbed onto the NP and released ([@b18]; [@b81]; [@b132]). Several toxicological studies support the contention that NPs in PM~10~ could drive inflammatory effects. There are a number of components of PM~10~ that contribute to the mass but have little toxicity -- these include salts such as sulfates, chlorides and ammonium salts and nitrates, but also wind-blown or crustal dust. In fact within PM~10~ there are only few components that toxicologists would identify as likely mediators of adverse effects -- ie, particle surfaces, organics, metals and endotoxin (in some PM~10~ samples). In fact, a large surface area, organics and metals are all characteristic of combustion--derived particles and so these have attracted considerable toxicological attention ([@b37]). However, it is difficult to untangle, in a combustion particle sample, the relative roles of surface, organics and metals, although this has been most attempted in vitro. The aggregation of multiple chemical species including biological compounds like endotoxin limits the extrapolation of the results on the toxicological effects of such particles.

Toxicological effects of nanoparticles
--------------------------------------

As already mentioned above, NPs exert some very special properties that are very relevant in the further design of toxicity testing of engineered nanomaterials. An overview of most striking effects of (nano) particles that have been observed over the last decades is given in [Table 4](#tbl4){ref-type="table"} along with the particle type that have been tested in this response. Several effects are just quantitatively different from fine particles. In this case nanoparticles may cause the same effects as 'traditional' particles (eg, inflammation, lung cancer) but they may be more potent because of their greater surface area.

###### 

Toxicity of engineered and combustion (nano) particles as illustrated by their most unique adverse effects in vivo and in vitro

  Description of finding, in vivo                                                                              Particle types
  ------------------------------------------------------------------------------------------------------------ -------------------------------------------
  NPs cause pulmonary inflammation in the rat                                                                  All PSP
  Later studies show that inflammation is mediated by surface area dose                                        SWCNT, MWCNT
  NPs cause more lung tumors than fine particles in rat chronic studies. Effect is surface area mediated       PSP only
  NPs cause progression of plague formation (ApoE -/- mice)                                                    SWCNT, PM2.5
  NPs affect immune response to common allergens                                                               Polystyrene, CB, DEP
  NsP can have access to systemic circulation upon inhalation and instillation                                 Specific NP, dependent on surface coating
  **Description of finding, in vitro**                                                                         
  NPs cause oxidative stress in vivo and in vitro, by inflammatory action and generation of surface radicals   PSP, NP general, CNT
  NPs inhibit macrophage phagocytosis, mobility and killing                                                    CB, TiO~2~
  NPs cause platelet aggregation                                                                               PM, SWCNT, fullerenes, latex-COOH surface
  NPs exposure adversely affects cardiac function and vascular homeostasis                                     PM, SWCNT
  NPs interfere with Ca-transport and cause increased binding of pro-inflammatory transcription factor NF-kB   CB (\< 100 nm), ROFA, PM2.5
  NPs can affect mitochondrial function                                                                        Ambient NP,
  NPs can translocate to the brain from the nose                                                               MnO~2~, Au, carbon
  NPs do affect rolling in hepatic tissue                                                                      CB

However, nanoparticles could also cause new types of effects not previously seen with larger particles (eg, mitochondrial damage, uptake through olfactory epithelium, platelet aggregation, cardiovascular effects). These effects depicted in [Table 4](#tbl4){ref-type="table"} clearly need a new way of handling their toxicology. In addition, epidemiological evidence suggests that these effects occur predominantly in subjects that have an impaired health. This finding should be considered in developing toxicological testing models.

### Effects on blood and cardiovascular system

As we discussed earlier, ligand coated engineered nanoparticles are being explored and used as agents for molecular imaging or drug delivery tools. This has led to a considerable understanding of particle properties that can affect penetration in tissue without affecting tissue function. Cationic NPs, including gold and polystyrene have been shown to cause hemolysis and blood clotting, while usually anionic particles are quite non-toxic. This conceptual understanding maybe used to prevent potential effects of unintended NP exposure. Similarly, drug loaded nanoparticles have been used to prolong half-life or reduce side-effects and have shown which particle properties need to be modified to allow delivery, while being biocompatible ([@b59]).

On the other hand, one is trying to find explanations for the increased risk of patients with cardiovascular diseases upon exposure to PM and/or traffic. Several toxicological studies have demonstrated that combustion and model NPs can gain access to the blood following inhalation or instillation and can enhance experimental thrombosis but it is not clear whether this was an effect of pulmonary inflammation or particles translocated to the blood ([@b105], [@b106]; [@b98]). High exposures to DEP by inhalation caused altered heart rate in hypertensive rats ([@b17]) interpreted as a direct effect of DEP on the pacemaker activity of the heart. Inflammation in distal sites has long been associated with destabilization of atheromatous plaques and both instillation and inhalation of PM cause morphological evidence of atheromatous plaque increase and destabilization in rabbits ([@b142]) and mice ([@b21]). Ultrafine carbon black instilled into the blood has been reported to induce platelet accumulation in the hepatic microvasculature of healthy mice in association with prothrombotic changes on the endothelial surface of the hepatic microvessels ([@b71]). Recent studies with carbon derived nanomaterials showed that platelet aggregation was induced by both single and multi-wall carbon nanotubes, but not by the C60-fullerenes that are used as building blocks for these CNT ([@b122]). These data show that not all nanomaterials act similar in this test, and that surface area is not the only factor playing a role here. The data also corroborate the earlier concept developed in medicine that mainly cationic species have an effect on blood clotting. Interestingly, this is the first study that allows bridging of data, since also a real life PM10 sample (SRM1648) was included in the test-series. Actually the PM sample showed a lower effect compared to the carbon nanotubes ([@b122]).

### Uptake and effects of nanoparticles in the brain

Nanoparticles can get access to the brain by two different mechanisms, ie, (1) transsynaptic transport after inhalation through the olfactory epithelium, and (2) uptake through the blood-brain barrier. The first pathway has been studied primarily with model particles such as carbon, Au and MnO~2~ in experimental inhalation models in rats ([@b109]; [@b112]). The second pathway has been the result of extensive research and particle surface manipulation in drug delivery ([@b78]; [@b77]; [@b146]). The latter studies suggest that the physiological barrier may limit the distribution of some proteins and viral particles after transvascular delivery to the brain, suggesting that the healthy BBB contains defense mechanisms protecting it from blood borne nanoparticle exposure. When nanoparticles with different surface characteristics were evaluated, neutral nanoparticles and low concentrations of anionic nanoparticles were found to have no effect on BBB integrity, whereas high concentrations of anionic nanoparticles and cationic nanoparticles were toxic for the BBB. Nanoparticles have been shown to induce the production of reactive oxygen species and oxidative stress ([@b104]) and this has been confirmed in the brain after inhalation of MnO~2~ nanoparticles ([@b43]). Oxidative stress has been implicated in the pathogenesis of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. Evidence for the involvement of ambient air nanoparticles in these effects is presented by studies in biopsies from city dwellers. Alzheimer's like pathology was demonstrated in brain sections by increased markers of inflammation and AB42-accumulation in frontal cortex and hippocampus in association with the presence of nanoparticles ([@b15]). Also inhalation exposure of BALB/c mice to particulate matter showed activation of pro-inflammatory cytokines in the brain ([@b16]). Whether this is due to the fraction of combustion nanoparticles remains to be investigated.

Current data on the toxicology engineered nanoparticles
=======================================================

In the past few years a number of papers have described the toxicology of newly engineered nanomaterials, including fullerenes ([@b128]), carbon nanotubes ([@b32]), quantum dots ([@b61]) and have illustrated that apart from size and surface area, many more parameters describing the material (surface) properties have to be included. In a recent report [@b25] reviewed the evidence for toxicity of NPs used in healthcare products. Her conclusions again stressed the limited availability of toxicity data of the NPs in use.

Carbon nanotubes
----------------

Carbon nanotubes are long carbon-based tubes that can be either single- or multiwalled and have the potential to act as biopersistent fibers. Nanotubes have aspect ratios \>100, with lengths of several mm and diameters of 0.7 to 1.5 nm for single-walled carbon nanotubes (SWCNT) and 2 to 50 nm for multiwalled carbon nanotubes (MWCNT). In vitro incubation of keratinocytes and bronchial epithelial cells with high doses of SWCNT results in ROS generation, lipid peroxidation, oxidative stress, mitochondrial dysfunction, and changes in cell morphology ([@b139]; [@b129]). Recent studies with carbon derived nanomaterials showed that platelet aggregation was induced by both single and multi-wall carbon nanotubes, but not by the C60-fullerenes that are used as building blocks for these CNT ([@b122]). MWCNT also elicit pro-inflammatory effects in keratinocytes ([@b100]). Several studies using intratracheal instillation of high doses of nanotubes in rodents demonstrated chronic lung inflammation, including foreign-body granuloma formation and interstitial fibrosis ([@b148]; [@b101]). In two in vivo studies SWCNTs were demonstrated to induce lung granulomas after intratracheal administration ([@b84]; [@b148]) indicating that these nanotubes can not be classified as a new form of graphite on material safety data sheets. On a dose per mass basis the nanotubes were more toxic than quartz particles well known for their lung toxicity. Carbon black, carbonyl iron and graphite produced no significant adverse effects ([@b84]; [@b148]). These studies also reveal the tendency of the nonphysiologic administration route and the unrealistic high doses to lead to asphyxiation through nanotube clumping in the airways ([@b148]; [@b101]). Although it has been suggested that the granulomatous inflammation could be a biopersistent fiber effect, the high dose of the aggregated nanotubes and the presence of metal impurities (eg, Fe) could account for artificial toxicity.

Fullerenes
----------

Fullerenes are being explored as potential new antimicrobial agents in view of their potency for induction of reactive oxygen species after photoexcitation ([@b153]). However, this may have an impact on microbial communities if they are released into the environment via effluents. Therefore, various studies with fullerenes have been published with regard to the ecotoxicity of these important building blocks in nanomaterials. Tests with un-coated, water soluble, colloidal fullerenes (nC60) show that the 48-hour LC50 in Daphnia magna varied form 460 to 800 ppb ([@b91]; [@b155]), using standard EPA protocols. However, for sonicated C-60 fullerenes the LC50 was one order of magnitiude higher with 7.9 ppm ([@b91]). In largemouth brass, although no mortality was seen, lipid peroxidation was seen in the brain and glutathione depletion in the gill after exposure to 0.5 ppm nC60 for 48 hours ([@b109]). There are several hypotheses as to how lipid damage may have occurred in the brain, including direct redox activity by fullerenes reaching the brain via circulation or axonal translocation and dissolving into the lipid-rich brain tissue, oxygen radical production by microglia, or production of reactive fullerene metabolites by cytochrome P450 metabolism.

Dendrimers
----------

Because of their specific nature dendrimers are specifically suited for drug delivery purposes. Although their small size (up to 10 nm) limits extensive drug incorporation into the dendrimers, their dendritic nature and branching allows for drug loading onto the outside surfaces of the polymeric structure ([@b143]). Functionalization of the surface with specific antibodies may further enhance potential targeting. Apart from application in drug-delivery, dendrimers are being investigated for many other uses including bacterial cell killing, as gene transfer agents and trans-membrane transport. Little published data is available on the toxicity of this class of particles. A recent review on this topic ([@b40]) concluded that it will only ever be possible to designate a dendrimers as "safe" when related to a specific application. The so far limited clinical experience with dendrimers makes it impossible to designate any particular chemistry intrinsically "safe" or "toxic".

Quantum dots
------------

Quantum dots are a heterogeneous group of nanoparticles (reviewed by [@b61]). Quantum dot absorption, distribution, metabolism and excretion, and therefore also quantum dot toxicity, depend on multiple factors derived from both inherent physicochemical properties and environmental conditions. Quantum dots may vary in size ranges from 2.5 up to 100 nm, depending on coating thickness. Studies specifically performed to investigate quantum dot toxicity are few ([@b61]). In vitro studies have indicated that quantum dots may be toxic ([@b65]; [@b138]; [@b92]) of which some toxicity could be attributed to the surface coating ([@b65], [@b66]). [@b23] demonstrated that quantum dot toxicity was reduced after surface modification with N-acetylcysteine, while the non modified cadmium telluride quantum dots induced lipid peroxidation in the cells. [@b93] showed "naked" quantum dots to be cytotoxic by induction of reactive oxygen species resulting in damage to plasma membranes, mitochondria and nucleus. As it is the bioactive coating which allows the use of quantum dots for specific targeting to cells and/or cell organelles, attention is warranted in using the surface molecules in terms of induction of toxic effects. However, also the quantum dot core material has an effect on the toxic potential of the quantum dots as for cadmium containing quantum dots the toxicity was suggested to be due to release of highly toxic free Cd^2+^ ions ([@b30]; [@b74]). For quantum dots composed of cadmiun/telluride cellular toxicity was found but not for cadmium selenium/zinc sulfate quantum dots ([@b22]). On the other hand [@b61] also reported on studies demonstrating a lack of both in vitro and in vivo toxicity. However, before there can be a responsible development of quantum dots with minimal risks more information on toxicological risks needs to be provided.

Gold nanoparticles/nanoshells
-----------------------------

In the summary of evaluations performed by the Joint FAO/WHO (Food and Agriculture Organization of the United Nations/World Health Organization) Expert Committee on Food Additives (JECFA) gold was not considered to present a hazard when used as coloring agent and food additive ([@b68]). However, such evaluations did not consider nanoformulations of gold. Metallic colloidal gold nanoparticles are widely used, can be synthesized in different forms (rods, dots), are commercially available in various size ranges and can be detected at low concentrations. Cells can take up gold nanoparticles without cytotoxic effects ([@b24]; [@b136]). For biomedical applications, they are used as potential carriers for drug delivery, imaging molecules and even genes ([@b70]), and for the development of novel cancer therapy products ([@b64]; [@b60]; [@b90]; [@b115]; [@b123]). For gold nanorods the cytotoxicity could be attributed to the presence of the stabilizer CTAB of which even residual presence after washing resulted in considerable cytotoxicity. PEG-modified gold nanorods with removing the excess CTAB did not show cytotoxicity ([@b107]). In an acute oral toxicity study no signs of gross toxicity or adverse effects were noted when a nanogold suspension (nanoparticle diameter ca. 50 nm) was evaluated, the single dose for acute oral LD~50~ being greater than 5000 mg/kg body weight ([@b83]).

Gold solutions are also used to prepare nanoshells composed of gold and copper, or gold and silver to function as contrast agents in Magnetic Resonance Imaging (RMI) ([@b141]), and gold-silica for photothermal ablation of tumor cells ([@b7]; [@b140]). In vitro the non targeted nanoshells did not show cytotoxicity for the tumor cells, whereas after binding to the tumor cells cell death could be obtained after laser activation ([@b94]; [@b7]; [@b140]). Also in vivo positive results were obtained with photothermal ablation therapy in a mouse model for colon carcinoma after intraveneous administration of PEG coated gold nanoshells of approximately 130 nm ([@b115]).

Silica
------

For silica nanoparticles both in vitro toxic and non toxic responses were observed. Both 15 nm and 46 nm silica nanoparticles showed similar dose dependent cytotoxicity in vitro ([@b87]). There was an increase in toxicity both at increasing doses and at increasing exposure time (24, 48, and 72 h). SiO~2~ exposure resulted in an increased ROS levels and reduced glutathione levels indicating an increase in oxidative stress. Also [@b20] found silica nanoparticles to be toxic at high dosages as shown by a reduction in cell viability/cell proliferation and by lactate dehydrogenase (LDH) release from the cells indicating membrane damage. Cells with a long doubling time were more susceptible for the cytotoxic effects of the silica nanoparticles than cells with short doubling times ([@b20]). In another study only at concentrations above 0.1 mg/ml a significant reduction in cell viability was observed ([@b69]). In addition, an alveolar macrophage cell line (MHS) was found to be more susceptible for nanaoparticle induced cytotoxicity than a lung epithelial cell line (A549) which was suggested to be due to the phagocytic properties of the macrophage cell line. Cell death was probably not caused by apoptosis ([@b69]). In contrast for cationic silica nanoparticles using amino-hexyl-amino-propyltrimethoxysilane as a surface modification low or no cell toxicity was observed ([@b124]).

Nanomaterials in medicine: needs
================================

Although there is a considerable amount of data on the toxicity of NPs, this data is mainly based on a small panel of NPs (combustion derived NPs, TiO~2~, CB) and the assumption that a lot of effects by particulate matter are driven by the ultrafine particle fraction in it ([@b33]; [@b112]; [@b10]). In most studies the nanoparticles were used as a model for ambient air particle toxicity. One of the more general conclusions is that indeed there is a clear tendency for very small (nano) particles to be more toxic than larger particles with the same chemical composition.

For nanoformulations used in drug delivery the focus in most papers is mainly on obtained reduction of toxicity of the incorporated drug, whereas the possible toxicity of the carrier used is not considered. Especially possible residues of such a treatment may harbor potential local and/or systemic toxic responses.

For medical applications certain routine assays need to be performed which will detect a number of potential hazards. However, it can be anticipated that not all hazards are at this moment known for the use of nanoparticles. In a recent report [@b25] reviewed the evidence for toxicity of NPs used in healthcare products. Her conclusions again stressed the limited availability of toxicity data of the NPs in use. However, in NPs for healthcare products most if not all mechanisms of toxicity could be identified by conventional hazard identification testing as currently required to comply with the regulations for healthcare products ([@b25]). Costigan identified four possible mechanisms of NP toxicity, being chemical toxicity of one of the constituents with the same mode of action as the bulk chemical, toxicity due to degradation products, toxicity due to endocytosis of the NPs, and membrane lysis due to the NPs possibly via chemical toxicity.

Although hazard identification is the general approach for safety evaluation of healthcare products, it is recommended to add testing driven by the anticipated application and classification by risk. Some engineered NPs, which get airborne will pose inhalation hazards, while cosmetics with NPs provide dermal exposures. For parenteral use interactions with blood components, systemic distribution and kinetics are of importance, when engineered NPs are being used as devices to target drugs to specific tissues, to increase their biological half time, or for imaging purposes. Each nanoparticle formulation should be tested on a case by case basis in the requisite ways focusing on their portal of entry. In this respect also the potential adverse (toxic) effects of empty particles should be considered. In developing testing procedures and protocols a number of basic issues need to be considered:

1.  Which effects are specific for nanomaterials, and which effects are merely stronger? Nanoparticles may cause the same effects as 'traditional' particles (eg, inflammation, lung cancer) but they may be more potent because of their greater surface area. Nanoparticles could also cause new types of effects not previously seen with larger particles or bulk chemicals.

2.  Can we extrapolate available data and concepts? The epidemiological evidence on ultrafine particles has revealed several effects, mechanisms of action and susceptible groups upon inhalation of ultrafine particles. Whether these concepts can be used for nanoparticles released from manufactured nanomaterials is yet unknown.

3.  Is our current regulation robust enough to handle risks of nanomaterials? We deal with a growing set of materials of which the properties are largely unknown and for which current testing procedures and legislation might produce false negatives and/or false positives. The central question here is whether current testing and classification protocols are appropriate or sufficient. These will detect certain toxic effects as demonstrated by the studies already published. However, it can be anticipated that not all hazards will be detected and additional specific testing may be needed. Nanotechnology also promotes convergence of technologies, and for example similar materials may be applied in the automotive and the life sciences sector. To stimulate production and marketing of safe nanomaterials exchange of data between sectors is recommended. Sharing of information on the toxicity of nanomaterials, will significantly reduce time to market for many products and producers.

4.  Should we use the precautionary principle in current regulatory testing? The precautionary principle (PP) is a highly debated issue in international politics and was first added in EU environmental regulation in the Maastricht treaty in Article 174 (ex Art 130r). The PP points out that scientific uncertainty is no reason for inaction if there might be strong adverse effects. It has been criticized for being too vague and too arbitrary to form a basis for rational decision-making. On the other hand the PP does not necessarily imply a complete ban of substances but may be applied in steps of decreasing uncertainty or perceived risk. It is typically applied where scientific information is insufficient, inconclusive or uncertain whilst at the same time there are indications that potential effects may occur. Approaches in risk governance range from early explorations by Swiss RE ([@b63]) to more recent detailed reviews such by [@b125] and the [@b62]. A crucial difference between both reports is that Renn and Roco place the nanotechnology *products themselves* into the risk issue categories rather than the risk issues that accompany the use of these products. This difference may seem trivial, but is important since it is the purpose and application rather than the device itself that connect hazard to exposure, and therefore creates a risk. For example, it fails to distinguish between brain implants for enhancement purposes and those for fighting tremor in Parkinson patients. This may pave the way to one nanotechnology product compromising or allowing all the others. Furthermore, it can convey the impression that the broader societal implications and accompanying ethical issues of nanotechnologies are as new as the nanotechnology products themselves, or even are still in the future. However, most of them are not.

Conclusions
===========

The use of Nanotechnology in medicine and more specifically drug delivery is set to spread rapidly. For decades pharmaceutical sciences have been using nanoparticles to reduce toxicity and side effects of drugs. Up to recently it was not realized that these carrier systems themselves may impose risks to the patient. The type of hazards that are introduced by using nanoparticles for drug delivery are beyond that posed by conventional hazards imposed by chemicals in delivery matrices. However, so far, the scientific paradigm for the possible (adverse) reactivity of nanoparticles is lacking and we have little understanding of the basics of the interaction of nanoparticles with living cells, organs and organisms. A conceptual understanding of biological responses to nanomaterials is needed to develop and apply safe nanomaterials in drug delivery in the future. Furthermore a close collaboration between those working in drug delivery and particle toxicology is necessary for the exchange of concepts, methods and know-how to move this issue ahead.
